Ziprasidone Mesylate 20 Mg/ml Injection, Powder, Lyophilized, For Solution
NDC Package 72485-430-10

11-digit billing NDC: 72485043010 · Billing unit: EA · 10 EA per package

Package Information

Ziprasidone Mesylate 20 Mg/ml (ziprasidone mesylate) injection is ziprasidone mesylate for injection is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. Ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Armas Pharmaceuticals Inc., this product is identified by NDC 72485-430 and is authorized under FDA application ANDA217595.

Identification & Billing

NDC Package Code
72485-430-10
Package Description
10 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE (72485-430-01)
Product Code
11-Digit Billing Format
72485043010
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
10 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ziprasidone Mesylate 20 Mg/ml
Non-Proprietary Name
Ziprasidone Mesylate
Substance Name
Ziprasidone Mesylate
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
Usage Information
Ziprasidone mesylate for injection is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. Ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3)] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.3)] .

Regulatory & Marketing

Labeler Name
Armas Pharmaceuticals Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA217595
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-21-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72485-430-10 identifies a specific commercial package of 10 vial, single-dose in 1 carton / 1 ml in 1 vial, single-dose (72485-430-01) of Ziprasidone Mesylate 20 Mg/ml, a human prescription drug labeled by Armas Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 10 billable units per package. This injection, powder, lyophilized, for solution is formulated for intramuscular use and contains ziprasidone mesylate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Armas Pharmaceuticals Inc. on September 21, 2026. The current certification is valid through December 31, 2027.

How is this Armas Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72485043010. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72485-430-10
11-Digit CMS (5-4-2)
72485-0430-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.